Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

EMA adopts positive opinion for Pfizer’s bosutinib conditional approval in the EU

Pfizer Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion regarding the conditional marketing authorization of bosutinib in the European Union for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitor(s) (TKIs) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.

19 Jan 2013

Sabutoclax appears to selectively target leukemia stem cells that are responsible for relapses

Researchers at the University of California, San Diego School of Medicine have discovered that hard-to-reach, drug-resistant leukemia stem cells (LSCs) that overexpress multiple pro-survival protein forms are sensitive - and thus vulnerable - to a novel cancer stem cell-targeting drug currently under development.

18 Jan 2013

Rochester scientists propose new reason why acute myeloid leukemia is so difficult to cure

University of Rochester Medical Center scientists have proposed a new reason why acute myeloid leukemia, one of the most aggressive cancers, is so difficult to cure: a subset of cells that drive the disease appear to have a much slower metabolism than most other tumors cells.

18 Jan 2013

RSAS honors Feinstein Institute scientist with Crafoord Prize for genetic research on arthritis

The Royal Swedish Academy of Sciences announced today that Peter K. Gregersen , MD, a scientist at The Feinstein Institute for Medical Research, will receive the prestigious Crafoord Prize for his genetic research in the area rheumatoid arthritis.

18 Jan 2013

Study finds key association between Kallikrein 6 and malignant tumors

One of the most common types of brain tumors in adults, glioblastoma multiforme, is one of the most devastating. Even with recent advances in surgery, radiation and chemotherapy, the aggressive and invasive tumors become resistant to treatment, and median survival of patients is only about 15 months. In a study published in Neuro-Oncology, researchers at Mayo Clinic identify an important association between the naturally occurring enzyme Kallikrein 6, also known as KLK6, and the malignant tumors.

18 Jan 2013

SF3B1 gene mutations in uveal melanoma linked to favorable features

Melanomas that develop in the eye often are fatal. Now, scientists at Washington University School of Medicine in St. Louis report they have identified a mutated gene in melanoma tumors of the eye that appears to predict a good outcome.

17 Jan 2013

Scientists to investigate how cancer cells hide to avoid chemotherapy drugs

Scientists hope to improve leukaemia treatment by investigating how cancer cells use 'hiding places' in the body to avoid chemotherapy drugs.

17 Jan 2013

Over-expression of NEK2 in cancer cells significantly enhances drug resistance

Increased NEK2 gene expression linked to increased drug resistance, faster cancer growth, and poorer patient outcome - The finding may improved diagnostic and prognostic tools for cancer care and could lead to improved cancer therapies

16 Jan 2013

Overall cancer death rates continue to decline in the U.S.: Report

The Annual Report to the Nation on the Status of Cancer, 1975-2009, shows that overall cancer death rates continued to decline in the United States among both men and women, among all major racial and ethnic groups, and for all of the most common cancer sites, including lung, colon and rectum, female breast, and prostate.

9 Jan 2013

CTI initiates enrollment in pacritinib Phase 3 trial for myelofibrosis

Cell Therapeutics, Inc. (CTI) today announced that the Company has initiated clinical trial sites and began enrolling patients in a Phase 3 clinical trial, known as PERSIST-1 or PAC325, for pacritinib, CTI's investigational JAK2 inhibitor, which is being evaluated for the treatment of patients with myelofibrosis.

9 Jan 2013

Seven scientists named 2013 recipients of Damon Runyon-Rachleff Innovation Award

The Damon Runyon Cancer Research Foundation announced that seven scientists with novel approaches to fighting cancer have been named 2013 recipients of the Damon Runyon-Rachleff Innovation Award.

8 Jan 2013

Inovio, MVI collaborate to advance malaria vaccine development and new delivery technologies

The PATH Malaria Vaccine Initiative (MVI) and Inovio Pharmaceuticals, Inc. today announced a follow-on collaboration to advance malaria vaccine development and new vaccination delivery technologies.

7 Jan 2013

Trovagene, MD Anderson partner to detect transrenal BRAF mutations in metastatic cancers

Trovagene, Inc., a developer of transrenal molecular diagnostics, announced that it has entered into a clinical collaboration with The University of Texas MD Anderson Cancer Center to detect transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers.

3 Jan 2013

Early problems in processing knowledge-based information linked to Alzheimer's disease

People who study or treat Alzheimer's disease and its earliest clinical stage, mild cognitive impairment (MCI), have focused attention on the obvious short-term memory problems. But a new study suggests that people on the road to Alzheimer's may actually have problems early on in processing semantic or knowledge-based information, which could have much broader implications for how patients function in their lives.

29 Dec 2012

Trovagene adds Duke University Health System to worldwide licensees of NPM1 marker for AML

Trovagene, Inc., a developer of transrenal molecular diagnostics, announced it has granted Duke University and Duke University Health Systems a non-exclusive license to incorporate nucleophosmin protein (NPM1) into research and clinical testing services for acute myelogenous leukemia (AML).

27 Dec 2012

Cancer-associated inflammation boosts ADAR1 enzyme activity

An international team, headed by researchers at the University of California, San Diego School of Medicine, has identified a key enzyme in the reprogramming process that promotes malignant stem cell cloning and the growth of chronic myeloid leukemia (CML), a cancer of the blood and marrow that experts say is increasing in prevalence.

25 Dec 2012

CNIO creates 2 new databases to study the human genome

Scientists from the Structural Computational Biology Group at the Spanish National Cancer Research Centre (CNIO), led by Alfonso Valencia, together with French and American researchers, have published recently two articles in the journal Nucleic Acid Research (NAR) that introduce two new databases for studying the human genome.

18 Dec 2012

Researchers identify possible heredity mechanism that predisposes children to ALL

Researchers at the Sainte-Justine University Hospital Center and the University of Montreal have found a possible heredity mechanism that predisposes children to acute lymphoblastic leukemia (ALL), the most common type of blood cancer in children. According to their findings published in Genome Research, the presence of a genetic defect in the egg or sperm from which children having ALL arise may be a prerequisite for the disease to develop.

17 Dec 2012

New technique could help develop more-specific, cell-based immune therapies for cancer

A team led by Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at Memorial Sloan-Kettering Cancer Center, has shown for the first time the effectiveness of a new technique that could allow the development of more-specific, cell-based immune therapies for cancer.

17 Dec 2012

Researchers identify 125 genetic components in temozolomide-resistant, GBM-derived cell line

University of Pittsburgh Cancer Institute (UPCI) researchers have identified over 125 genetic components in a chemotherapy-resistant, brain tumor-derived cell line, which could offer new hope for drug treatment to destroy the cancer cells.

15 Dec 2012

Leukemia News and Research

Further Reading

EMA adopts positive opinion for Pfizer’s bosutinib conditional approval in the EU

Sabutoclax appears to selectively target leukemia stem cells that are responsible for relapses

Rochester scientists propose new reason why acute myeloid leukemia is so difficult to cure

RSAS honors Feinstein Institute scientist with Crafoord Prize for genetic research on arthritis

Study finds key association between Kallikrein 6 and malignant tumors

SF3B1 gene mutations in uveal melanoma linked to favorable features

Scientists to investigate how cancer cells hide to avoid chemotherapy drugs

Over-expression of NEK2 in cancer cells significantly enhances drug resistance

Overall cancer death rates continue to decline in the U.S.: Report

CTI initiates enrollment in pacritinib Phase 3 trial for myelofibrosis

Seven scientists named 2013 recipients of Damon Runyon-Rachleff Innovation Award

Inovio, MVI collaborate to advance malaria vaccine development and new delivery technologies

Trovagene, MD Anderson partner to detect transrenal BRAF mutations in metastatic cancers

Early problems in processing knowledge-based information linked to Alzheimer's disease

Trovagene adds Duke University Health System to worldwide licensees of NPM1 marker for AML

Cancer-associated inflammation boosts ADAR1 enzyme activity

CNIO creates 2 new databases to study the human genome

Researchers identify possible heredity mechanism that predisposes children to ALL

New technique could help develop more-specific, cell-based immune therapies for cancer

Researchers identify 125 genetic components in temozolomide-resistant, GBM-derived cell line

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News